Contrasting this, the subset of HER2‐positive patients who did not receive anti‐HER2 therapy showed a significantly higher risk of recurrence when their BC displayed a positive HER2 morphometric signature (p = 0.048). This evidence concerns the gene ERBB2 and breast cancer.